IRLAB CEO interview at NLS Days in Malmö, Sweden
IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's.
We spoke with IRLAB CEO Richard Godfrey at NLS Days in Malmö.
➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin: / 5312453
Twitter: / labiotech_eu
Facebook: / labiotech.eu
Instagram: / labiotech.eu
About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.
@irlabtherapeutics2361
#biotech #parkinson #neurologicaldisorders